Saudi Press: Saudi Arabia Expresses Solidarity with Lebanon after Beirut's Port Explosion    Under the Directives of the Custodian of the Two Holy Mosques, Saudi Arabia Provides Urgent Humanitarian Assistance to Confront Effects of Beirut Port Explosion    HSBC arranges inaugural green ECA loan for Ministry of Finance    No injuries as firefighters put out Ajman market blaze    Mexico Nears 50,000 Coronavirus Deaths, with 829 New Fatalities    Woman infected with coronavirus gives birth to healthy triplets in Al-Jouf    UAE COVID-19 vaccine trial expands, with second center set up in Sharjah    King Salman directs urgent aid to Lebanon through KSrelief    Woman infected with coronavirus gives birth to healthy triplets in Al-Jouf    Facebook launches its new TikTok clone, Instagram Reels    Black Lives Matters activist ousts veteran Missouri congressman    RGDHS to Bring Together Global Healthcare Innovators to Set Out Roadmap for Fighting Pandemics    France's New COVID-19 Cases up 1,695, More Than Two-Month High    Landmark Arabia, Alnahda Society partner to facilitate virtual learning    Alinma Bank announces net profit of SR1,048 million before zakat    Labor settlement wing handles 3,000 cases, clears SR5 million in dues    8 things NGOs can do to survive the pandemic    Sentiment mixed on lingering US fiscal talks, Beirut explosion as gold moves past $2,022    Lebanon declares emergency in Beirut, approves urgent funding    Training on coronavirus measures important before start of new academic year: Al-Sheikh    KSrelief Supports Lebanese Medical Teams to Help People Affected by Beirut Port Explosion    Asia shares mixed    HRH Crown Prince Congratulates Governor-General of Jamaica on Independence Day    Ebrahim Alkazi, India's theater legend, dies at 95    Summer training camp perfect preparation for UAE's jiu-jitsu stars    LaLiga Academy UAE launches its 2020/2021 season at its new home at DSC    Umm Kulthum hologram to perform at Dubai Opera    Long-awaited Riyadh derby, SPL games will finally kick-off with safety measures in place    UAE Team Emirates on the podium at Strade Bianche    India's top minister Amit Shah tests positive for coronavirus    Aubameyang double helps Arsenal beat Chelsea for 14th FA Cup trophy    Azra Aly, South African pilgrim: ‘The beginning of the rest of my life'    Paris Saint-Germain beats Lyon to win League Cup final    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Islam calls for protecting communities against epidemics: Sheikh Al-Manea    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Saudi Waste Management Center Signs MoU to Enhance Environmental Sustainability in Saudi Arabia    Bahrain Bourse Rises    Cruise Ships on Saudi Arabia's Red Sea Coasts Launched    Juventus claim ninth successive Serie A title with win over Sampdoria    Muslims in UAE asked to perform Eid Al-Adha prayers at home    Paplo Larazapal appointed international ambassador for Saudi golf    Complementary, Alternative Medicine Practicing 1st Manual Version Issued    Saudi Ithra center launches dialogue sessions with most famous creators in the world    SFDA Implements National Program to Ensure Safety of 10,000 Food Samples    Saudi Surgeon Managed to Remove Kuwaiti Girl's Brain Tumor, as French Physician Declined, in the last Moments    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    Custodian of the Two Holy Mosques Addresses Citizens and Muslims on Eid Al-Fitr    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

India approves Glenmark's FabiFlu for corona treatment
Published in The Saudi Gazette on 20 - 06 - 2020

Glenmark Pharmaceuticals new antiviral drug — Favipiravir with brand name FabiFlu — has been cleared for the treatment of mild to moderate COVID-19 patients in India.
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement after it received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday. FabiFlu will be marketed in some north Indian states soon.
The firm has become the first Indian company to commercially launch the antiviral drug.
"This approval comes at a time when COVID-19 cases in India are spiraling like never before, putting tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The medicine has produced up to 88% improvement in mild to moderate coronavirus patients during clinical trials, making it the first oral antiviral drug available under emergency use authorization to treat COVID-19 patients in India.
A pack of 34 tablets of FabiFlu has been priced at Rs.3,500 (Rs. 103 per tablet). The dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets a day for 14 days of the treatment.
However, it should only be taken after a doctor's prescription. A clinical trial was conducted by Glenmark among 90 mild and 60 moderate COVID-19 patients across 11 sites in India. The drug is claimed to have an efficacy of over 80% in the treatment of mild to moderate COVID-19 patients.
Delhi-based Brinton Pharmaceuticals, Bengaluru-based Strides Pharma, Mumbai-based Lasa Supergenerics and Hyderabad-based Optimus Pharma are some of the other Indian firms that have applied for approval and are readying for its launch in India, according to sources.
A study combining two anti-viral drugs, Favipiravir (an approved drug for novel flu pandemics) with Umifenovir (an approved drug for Influenza) in COVID-19 patients is also being undertaken by Glenmark.
Favipiravir is already being used commercially in the therapeutic management of COVID-19 in Bangladesh and UAE. It is sold under the brand name Avigan by Fujifilm Toyama Chemical and is approved in Japan since 2014 in treating influenza.
It is under the approval process in Egypt and Jordan and is a part of the treatment protocol in Russia, Japan and Saudi Arabia. About 18 global clinical trials in 3,000 subjects are going on including in India, USA, Canada, Italy, China, France, UK and other countries. — Agencies

Clic here to read the story from its source.